Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label extension study of long-term ALN-GO1 in primary hyperoxaluria type 1
MOH_2018-01-15_002097Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jan 2018
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of lumasiran in Primary Hyperoxaluria Type 1 (PH1) (2 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Long-term safety. Started Jan 2018; status: completed.
02
Drugs
lumasiran
03
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Beyond the preview
Go deeper on MOH_2018-01-15_002097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-01-15_002097.